Parkman Healthcare Partners LLC Acquires New Holdings in 4D Molecular Therapeutics, Inc. $FDMT

Key Points

• Parkman Healthcare Partners acquired 948,184 shares of 4D Molecular Therapeutics, worth approximately $12.6 million, giving it an estimated 1.81% stake. Institutional investors collectively own 99.27% of FDMT.
• Analyst sentiment is broadly positive, with an average “Moderate Buy” rating and a $29.62 price target, although Weiss Ratings issued a “sell” rating. Several major firms, including Goldman Sachs and HC Wainwright, maintained buy recommendations.
• FDMT reported a quarterly loss of $1.04 per share, slightly worse than estimates, while revenue of $3.78 million exceeded forecasts. The stock opened at $15.39, near its 52-week high of $16.93, while insiders sold more than 200,000 shares over the past 90 days.

Parkman Healthcare Partners LLC bought a new position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 948,184 shares of the company's stock, valued at approximately $12,611,000. Parkman Healthcare Partners LLC owned about 1.81% of 4D Molecular Therapeutics at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in FDMT. BlackRock Inc. purchased a new stake in 4D Molecular Therapeutics during the 2nd quarter valued at $60,463,000. Janus Henderson Group PLC boosted its stake in shares of 4D Molecular Therapeutics by 164.4% in the 4th quarter. Janus Henderson Group PLC now owns 4,635,875 shares of the company's stock worth $34,726,000 after buying an additional 2,882,508 shares during the last quarter. State Street Corp grew its holdings in shares of 4D Molecular Therapeutics by 197.5% in the fourth quarter. State Street Corp now owns 2,688,880 shares of the company's stock worth $20,167,000 after acquiring an additional 1,785,106 shares during the period. RA Capital Management L.P. grew its holdings in shares of 4D Molecular Therapeutics by 23.9% in the fourth quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company's stock worth $42,399,000 after acquiring an additional 1,090,000 shares during the period. Finally, Adage Capital Partners GP L.L.C. increased its position in 4D Molecular Therapeutics by 605.8% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,235,156 shares of the company's stock valued at $9,264,000 after acquiring an additional 1,060,156 shares during the last quarter. Institutional investors own 99.27% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on FDMT. The Goldman Sachs Group reissued a "buy" rating and issued a $32.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday, August 13th. HC Wainwright restated a "buy" rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Monday, July 20th. Chardan Capital raised shares of 4D Molecular Therapeutics to a "strong-buy" rating in a research report on Tuesday, July 28th. B. Riley Financial reiterated a "buy" rating on shares of 4D Molecular Therapeutics in a research note on Monday, August 17th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, 4D Molecular Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $29.62.

Insider Activity

In related news, insider David Kirn sold 114,746 shares of the business's stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $10.47, for a total transaction of $1,201,390.62. Following the completion of the transaction, the insider directly owned 942,485 shares in the company, valued at approximately $9,867,817.95. The trade was a 10.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Scott Bizily sold 9,810 shares of the business's stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total value of $117,720.00. Following the transaction, the insider owned 8,617 shares of the company's stock, valued at approximately $103,404. This trade represents a 53.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 200,496 shares of company stock worth $2,240,244 in the last ninety days. Corporate insiders own 7.90% of the company's stock.

4D Molecular Therapeutics Trading Down 2.8%

NASDAQ:FDMT opened at $15.39 on Tuesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 8.03 and a quick ratio of 8.03. The firm has a market capitalization of $850.14 million, a price-to-earnings ratio of -5.85 and a beta of 2.73. 4D Molecular Therapeutics, Inc. has a one year low of $5.97 and a one year high of $16.93. The business has a fifty day moving average price of $11.74 and a 200-day moving average price of $10.17.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%.The company had revenue of $3.78 million during the quarter, compared to the consensus estimate of $3.62 million. Sell-side analysts forecast that 4D Molecular Therapeutics, Inc. will post -4.09 EPS for the current year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D's pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source